Velentium, LLC

Velentium, LLC is a medical device company specializing in the design and manufacturing of innovative healthcare solutions, focusing on translating complex medical concepts into practical applications. Founded in 2012, Velentium, LLC is located in Katy, Texas, US. The company designs and manufactures medical devices, providing comprehensive solutions from concept development to commercial launch. Co-founded by Alice Cali and Monique Reis, Velentium has successfully completed 2 deals, with the most recent deal occurring on July 16, 2024.

Velentium Medical specializes in the design and manufacturing of medical devices, offering solutions that range from initial concept development to commercial launch. Their core offerings include medical contract manufacturing, neuro and cardio active implant design, and a suite of research and development services that cover usability, electrical, firmware, mechanical, mobile, and cloud engineering. Velentium is ISO 13485 certified and operates as an FDA-registered manufacturer, ensuring compliance with stringent industry standards. The company serves a diverse client base of medical device companies across North America and Europe, aiding in the deployment of devices to healthcare providers worldwide.

Velentium Medical generates revenue through B2B transactions, collaborating with medical device firms in need of expert design and manufacturing services. The company's partnerships typically involve a mix of product development projects and ongoing contract manufacturing agreements, which may include upfront fees for development services and recurring charges based on production volumes. Velentium’s focus on quality and compliance fosters long-term contracts and collaborations within the medical device sector. In July 2024, Velentium secured USD 15 million in debt financing from Trinity Capital Investment, which will enhance the company's product innovation and support further growth initiatives.

The company is actively developing new medical devices aimed at expanding its portfolio and entering new markets across North America and Europe by the end of 2025.